{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T19:03:11Z","timestamp":1785438191488,"version":"3.56.0"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82372722"],"award-info":[{"award-number":["82372722"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373425"],"award-info":[{"award-number":["82373425"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["23Y11904200"],"award-info":[{"award-number":["23Y11904200"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.lungcan.2025.108890","type":"journal-article","created":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T00:02:50Z","timestamp":1766793770000},"page":"108890","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Inavolisib for PIK3CA-mutant non-small cell lung cancer: A case report"],"prefix":"10.1016","volume":"212","author":[{"given":"Lei","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baohui","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3009-9908","authenticated-orcid":false,"given":"Wei","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.lungcan.2025.108890_b0005","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/ng.3564","article-title":"Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas","volume":"48","author":"Campbell","year":"2016","journal-title":"Nat. Genet."},{"issue":"2","key":"10.1016\/j.lungcan.2025.108890_b0010","article-title":"PIK3CA mutations frequently coexist with EGFR\/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR\/KRAS wildtype subgroup","volume":"9","author":"Wang","year":"2014","journal-title":"PLoS One"},{"issue":"75","key":"10.1016\/j.lungcan.2025.108890_b0015","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002003","article-title":"Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors","volume":"3","author":"Sequist","year":"2011","journal-title":"Sci. Transl. Med."},{"issue":"4","key":"10.1016\/j.lungcan.2025.108890_b0020","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.cllc.2012.12.001","article-title":"Preclinical rationale for PI3K\/Akt\/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer","volume":"14","author":"Gadgeel","year":"2013","journal-title":"Clin. Lung Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2025.108890_b0025","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/s41467-023-35961-y","article-title":"Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer","volume":"14","author":"Chmielecki","year":"2023","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.lungcan.2025.108890_b0030","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1016\/j.jtho.2019.05.029","article-title":"SWOG S1400B (NCT02785913), a phase II study of GDC-0032 (Taselisib) for previously treated PI3K-positive patients with stage IV squamous cell lung cancer (Lung-MAP Sub-Study)","volume":"14","author":"Langer","year":"2019","journal-title":"J. Thorac. Oncol."},{"issue":"8","key":"10.1016\/j.lungcan.2025.108890_b0035","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1001\/jama.2019.11058","article-title":"Systemic therapy for locally advanced and metastatic non-small cell lung cancer: a review","volume":"322","author":"Arbour","year":"2019","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.lungcan.2025.108890_b0040","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1102\/1470-7330.2012.0027","article-title":"Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab","volume":"12","author":"Nishino","year":"2012","journal-title":"Cancer Imaging"},{"key":"10.1016\/j.lungcan.2025.108890_b0045","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3389\/fnmol.2011.00051","article-title":"PI3K\/AKT\/mTOR pathway in angiogenesis","volume":"4","author":"Karar","year":"2011","journal-title":"Front. Mol. Neurosci."},{"issue":"17","key":"10.1016\/j.lungcan.2025.108890_b0050","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1056\/NEJMoa2404625","article-title":"Inavolisib-based therapy in PIK3CA-mutated advanced breast cancer","volume":"391","author":"Turner","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.lungcan.2025.108890_b0055","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer","volume":"380","author":"Andr\u00e9","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.lungcan.2025.108890_b0060","doi-asserted-by":"crossref","first-page":"4333","DOI":"10.1002\/cncr.28376","article-title":"The symptom burden of cancer: evidence for a core set of cancer-related and treatment-related symptoms from the eastern cooperative oncology group symptom outcomes and practice patterns study","volume":"119","author":"Cleeland","year":"2013","journal-title":"Cancer"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225007822?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225007822?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T13:55:17Z","timestamp":1773928517000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500225007822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":12,"alternative-id":["S0169500225007822"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108890","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inavolisib for PIK3CA-mutant non-small cell lung cancer: A case report","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108890","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108890"}}